Neuropeptide Y Receptors Switch Their Role in Pain Depending on Whether You're Injured or Not

The review resolves conflicting findings about the NPY Y2 receptor by proposing a G protein switch model. In the normal state, blocking Y2 receptors (with BIIE0246) causes pain and hypersensitivity. After nerve injury or inflammation, the same Y2 blocker paradoxically reduces mechanical and thermal hypersensitivity and improves the emotional dimension of pain. In chronic pain models of latent sensitization, Y2 blockade causes a profound return of pain-like behaviors. This suggests Y2 signaling switches from antinociception (normal) to anti-hyperalgesia (injured) and back to antinociception (remission).

This is a narrative review synthesizing evidence from neurophysiological slice recordings, behavioral pharmacology studies in animal models, and chronic pain models of latent sensitization. The authors integrated findings across multiple experimental paradigms to propose a unified mechanistic model.

The opioid crisis has created urgent demand for non-opioid pain therapies. NPY Y2 receptors represent a largely untapped target in the spinal pain pathway. By clarifying when Y2 antagonists help versus hurt, this review provides a roadmap for developing targeted Y2-based therapies for chronic pain patients — specifically those who do not develop latent sensitization.

Neuropeptide Y is one of the most abundant peptides in the central nervous system, yet its therapeutic potential for pain has been complicated by contradictory findings. This review's proposed switch model brings clarity to a confusing field and could catalyze drug development efforts. As the pharmaceutical industry searches for non-opioid analgesics, peptide receptor targets like Y2 are increasingly attractive because they can modulate pain signaling with potentially fewer side effects than broad-acting drugs.

This is a review paper synthesizing primarily animal studies — the proposed G protein switch model has not been directly confirmed in humans. The behavioral pharmacology data relies heavily on a single Y2 antagonist (BIIE0246), and off-target effects cannot be entirely ruled out. The concept of latent sensitization and its relevance to human chronic pain conditions is still being established. Clinical translation remains speculative.